Hudson Bay Capital Management LP Has $11.66 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hudson Bay Capital Management LP boosted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 27.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 920,108 shares of the company's stock after buying an additional 200,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.91% of Day One Biopharmaceuticals worth $11,658,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DAWN. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth about $31,000. Tower Research Capital LLC TRC lifted its holdings in shares of Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after acquiring an additional 9,603 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $143,000. KLP Kapitalforvaltning AS bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $150,000. Finally, Optimize Financial Inc bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $196,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on DAWN shares. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reissued an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $30.57.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company's stock, valued at approximately $473,639.92. This trade represents a 10.50% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,064 shares of company stock worth $251,925. 6.20% of the stock is currently owned by insiders.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN traded up $0.09 during trading hours on Friday, reaching $6.25. The company's stock had a trading volume of 2,739,476 shares, compared to its average volume of 1,104,977. The firm has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $10.79. The stock has a market cap of $633.51 million, a P/E ratio of -6.07 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 52 week low of $6.08 and a 52 week high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. On average, research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.